相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The effect of metformin on biomarkers associated with breast cancer outcomes: a systematic review, meta-analysis, and dose-response of randomized clinical trials
J. Rahmani et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2020)
Metformin in breast cancer: preclinical and clinical evidence
Anindita De et al.
CURRENT PROBLEMS IN CANCER (2020)
The efficacy and safety of dipeptidyl peptidase-4 inhibitors for type 2 diabetes: a Bayesian network meta-analysis of 58 randomized controlled trials
Juan Ling et al.
ACTA DIABETOLOGICA (2019)
Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus
Eri T. Kato et al.
CIRCULATION (2019)
Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction Subanalysis From the DECLARE-TIMI 58 Trial
Remo H. M. Furtado et al.
CIRCULATION (2019)
SGLT2 inhibitors and metformin: Dual antihyperglycemic therapy and the risk of metabolic acidosis in type 2 diabetes
Katherine Donnan et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2019)
Metformin use and prostate cancer risk A meta-analysis of cohort studies
Zhaohan Feng et al.
MEDICINE (2019)
Nutrition Therapy for Adults With Diabetes or Prediabetes: A Consensus Report
Alison B. Evert et al.
DIABETES CARE (2019)
Meta-analyses of the effects of DPP-4 inhibitors, SGLT2 inhibitors and GLP1 receptor analogues on cardiovascular death, myocardial infarction, stroke and hospitalization for heart failure
Binayak Sinha et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2019)
Cardiorespiratory fitness, muscular strength and risk of type 2 diabetes: a systematic review and meta-analysis
Jakob Tarp et al.
DIABETOLOGIA (2019)
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
V. Perkovic et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Understanding the mechanisms of reversal of type 2 diabetes
Roy Taylor et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial
Lawrence A. Leiter et al.
CARDIOVASCULAR DIABETOLOGY (2019)
Drug repurposing to overcome resistance to various therapies for colorectal cancer
Winnie Fong et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2019)
Dipeptidyl Peptidase 4 Inhibitors and Risk of Inflammatory Bowel Disease Among Patients With Type 2 Diabetes: A Meta-analysis of Randomized Controlled Trials
Guangyao Li et al.
DIABETES CARE (2019)
Sodium glucose cotransporter 2 inhibitors and risk of genital mycotic and urinary tract infection: A population-based study of older women and men with diabetes
Iliana C. Lega et al.
DIABETES OBESITY & METABOLISM (2019)
Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial
Hertzel C. Gerstein et al.
LANCET (2019)
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
Hertzel C. Gerstein et al.
LANCET (2019)
Benefits of the Mediterranean diet: Epidemiological and molecular aspects
Lluis Serra-Majem et al.
MOLECULAR ASPECTS OF MEDICINE (2019)
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Mansoor Husain et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program
Zien Zhou et al.
DIABETOLOGIA (2019)
Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial
Julio Rosenstock et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
The role of an anti-diabetic drug metformin in the treatment of endocrine tumors
Shilpa Thakur et al.
JOURNAL OF MOLECULAR ENDOCRINOLOGY (2019)
Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial
Ofri Mosenzon et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
Soren L. Kristensen et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk The CARMELINA Randomized Clinical Trial
Julio Rosenstock et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
S. D. Wiviott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Resistance Exercise Intensity is Correlated with Attenuation of HbA1c and Insulin in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis
Yubo Liu et al.
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH (2019)
Physical Exercise as Therapy for Type 2 Diabetes Mellitus: From Mechanism to Orientation
Dan Yang et al.
ANNALS OF NUTRITION AND METABOLISM (2019)
SGLT-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials
Robert Puckrin et al.
ACTA DIABETOLOGICA (2018)
Myocardial Infarction Subtypes in Patients With Type 2 Diabetes Mellitus and the Effect of Liraglutide Therapy (from the LEADER Trial)
Steven P. Marso et al.
AMERICAN JOURNAL OF CARDIOLOGY (2018)
Comparative cardiovascular outcomes in the era of novel anti-diabetic agents: a comprehensive network meta-analysis of 166,371 participants from 170 randomized controlled trials
Xiao-dong Zhuang et al.
CARDIOVASCULAR DIABETOLOGY (2018)
Effect of Liraglutide on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Polyvascular Disease Results of the LEADER Trial
Subodh Verma et al.
CIRCULATION (2018)
Comparing SGLT-2 inhibitors to DPP-4 inhibitors as an add-on therapy to metformin in patients with type 2 diabetes: A systematic review and meta-analysis
B. M. Mishriky et al.
DIABETES & METABOLISM (2018)
Efficacy and Safety of IDegLira Versus Basal-Bolus Insulin Therapy in Patients With Type 2 Diabetes Uncontrolled on Metformin and Basal Insulin: The DUAL VII Randomized Clinical Trial
Liana K. Billings et al.
DIABETES CARE (2018)
Impact of Intensive Lifestyle Intervention on Disability-Free Life Expectancy: The Look AHEAD Study
Edward W. Gregg et al.
DIABETES CARE (2018)
Analysis of Fractures in Patients With Type 2 Diabetes Treated With Empagliflozin in Pooled Data From Placebo-Controlled Trials and a Head-to-Head Study Versus Glimepiride
Sven Kohler et al.
DIABETES CARE (2018)
Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial
Richard E. Pratley et al.
DIABETES OBESITY & METABOLISM (2018)
Short and medium-term efficacy of sodium glucose co-transporter-2 (SGLT-2) inhibitors: A meta-analysis of randomized clinical trials
Matteo Monami et al.
DIABETES OBESITY & METABOLISM (2018)
Long-term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension study
Ronnie Aronson et al.
DIABETES OBESITY & METABOLISM (2018)
Biosimilar vs originator insulins: Systematic review and meta-analysis
Tomohide Yamada et al.
DIABETES OBESITY & METABOLISM (2018)
Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy
Tina Vilsboll et al.
DIABETES OBESITY & METABOLISM (2018)
Effect of exenatide QW or placebo, both added to titrated insulin glargine, in uncontrolled type 2 diabetes: The DURATION-7 randomized study
Cristian Guja et al.
DIABETES OBESITY & METABOLISM (2018)
Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study
Paola Fioretto et al.
DIABETES OBESITY & METABOLISM (2018)
Metformin in cancer
Ritwika Mallik et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2018)
Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular disease, death and safety outcomes in type 2 diabetes - A systematic review
Karin Radholm et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2018)
Switching to insulin glargine 300 U/mL: Is duration of prior basal insulin therapy important?
Riccardo C. Bonadonna et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2018)
HbA1c measurement in Germany: Is the quality sufficient for follow-up and diagnosis?
Lutz Heinemann et al.
DIABETOLOGIE UND STOFFWECHSEL (2018)
A randomized, open-label, comparative, crossover trial on preference, efficacy, and safety profiles of lispro insulin u-100 versus concentrated lispro insulin u-200 in patients with type 2 diabetes mellitus: a possible contribution to greater treatment adherence
Sandro Gentile et al.
EXPERT OPINION ON DRUG SAFETY (2018)
Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes A Systematic Review and Meta-analysis
Sean L. Zheng et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)
Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial
Helena W. Rodbard et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2018)
Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial
Michael E. J. Lean et al.
LANCET (2018)
Does lower limb amputation concern all SGLT2 inhibitors?
Andre J. Scheen
NATURE REVIEWS ENDOCRINOLOGY (2018)
被撤回的出版物: Relationship between Clinic and Ambulatory Blood-Pressure Measurements and Mortality (Retracted article. See vol. 382, pg. 786, 2020)
J. R. Banegas et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: population based cohort study
Devin Abrahami et al.
BMJ-BRITISH MEDICAL JOURNAL (2018)
Dietary and nutritional approaches for prevention and management of type 2 diabetes
Nita G. Forouhi et al.
BMJ-BRITISH MEDICAL JOURNAL (2018)
Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysis
Muhammad Shariq Usman et al.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2018)
SGLT2 inhibitors and renal outcomes in type 2 diabetes with or without renal impairment: A systematic review and meta-analysis
Samuel Seidu et al.
PRIMARY CARE DIABETES (2018)
Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: population based cohort study
Devin Abrahami et al.
BMJ-BRITISH MEDICAL JOURNAL (2018)
Dietary and nutritional approaches for prevention and management of type 2 diabetes
Nita G. Forouhi et al.
BMJ-BRITISH MEDICAL JOURNAL (2018)
Association of Metformin Use With Risk of Lactic Acidosis Across the Range of Kidney Function A Community-Based Cohort Study
Benjamin Lazarus et al.
JAMA INTERNAL MEDICINE (2018)
Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis
M. Angelyn Bethel et al.
LANCET DIABETES & ENDOCRINOLOGY (2018)
Meta-Analysis of Sulfonylurea Therapy on Long-Term Risk of Mortality and Cardiovascular Events Compared to Other Oral Glucose-Lowering Treatments
W. Ryan Powell et al.
DIABETES THERAPY (2018)
Meta-Analysis of Sulfonylurea Therapy on Long-Term Risk of Mortality and Cardiovascular Events Compared to Other Oral Glucose-Lowering Treatments
W. Ryan Powell et al.
DIABETES THERAPY (2018)
Pitfalls in the Diagnosis of Diabetes: Are we too Lax with Laboratory Parameters?
Ruediger Landgraf et al.
DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT (2018)
2018 ESC/ESH Guidelines for the management of arterial hypertension
Bryan Williams et al.
EUROPEAN HEART JOURNAL (2018)
The Physical Activity Guidelines for Americans
Katrina L. Piercy et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
Adrian F. Hernandez et al.
LANCET (2018)
DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality
Thomas R. Pieber et al.
DIABETOLOGIA (2018)
Direct head-to-head comparison of glycaemic durability of dipeptidyl peptidase-4 inhibitors and sulphonylureas in patients with type 2 diabetes mellitus: A meta-analysis of long-term randomized controlled trials
Kang Chen et al.
DIABETES OBESITY & METABOLISM (2018)
Better glycaemic control and less hypoglycaemia with insulin glargine 300 U/mL vs glargine 100 U/mL: 1-year patient-level meta-analysis of the EDITION clinical studies in people with type 2 diabetes
Robert Ritzel et al.
DIABETES OBESITY & METABOLISM (2018)
Identification of barriers to insulin therapy and approaches to overcoming them
David Russell-Jones et al.
DIABETES OBESITY & METABOLISM (2018)
Therapeutic inertia in the treatment of hyperglycaemia in patients with type 2 diabetes: A systematic review
Kamlesh Khunti et al.
DIABETES OBESITY & METABOLISM (2018)
Empagliflozin and Assessment of Lower-Limb Amputations in the EMPA-REG OUTCOME Trial
Silvio E. Inzucchi et al.
DIABETES CARE (2018)
Combined Analysis of Three Large Interventional Trials With Gliptins Indicates Increased Incidence of Acute Pancreatitis in Patients With Type 2 Diabetes
Ivan Tkac et al.
DIABETES CARE (2017)
Cardiovascular events and all-cause mortality associated with sulphonylureas compared with other antihyperglycaemic drugs: A Bayesian meta-analysis of survival data
Steve Bain et al.
DIABETES OBESITY & METABOLISM (2017)
Addition of or switch to insulin therapy in people treated with glucagon-like peptide-1 receptor agonists: A real-world study in 66 583 patients
Olga Montvida et al.
DIABETES OBESITY & METABOLISM (2017)
Cardiovascular effects of dipeptidyl peptidase-4 inhibitor in diabetic patients with and without established cardiovascular disease: a meta-analysis and systematic review
Shishi Xu et al.
POSTGRADUATE MEDICINE (2017)
Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Risk of Diabetic Ketoacidosis after Initiation of an SGLT2 Inhibitor
Michael Fralick et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
Rury R. Holman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Bruce Neal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Liraglutide and Renal Outcomes in Type 2 Diabetes
Johannes F. E. Mann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Objectively Assessed Physical Activity and Weight Loss Maintenance among Individuals Enrolled in a Lifestyle Intervention
Jessica L. Unick et al.
OBESITY (2017)
Effect of Dipeptidyl Peptidase-4 Inhibitors on Heart Failure: A Network Meta-Analysis
Wen-Qin Guo et al.
VALUE IN HEALTH (2017)
Incretin based treatments and mortality in patients with type 2 diabetes: systematic review and meta-analysis
Jiali Liu et al.
BMJ-BRITISH MEDICAL JOURNAL (2017)
Incretin based treatments and mortality in patients with type 2 diabetes: systematic review and meta-analysis
Jiali Liu et al.
BMJ-BRITISH MEDICAL JOURNAL (2017)
Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial
David Z. I. Cherney et al.
LANCET DIABETES & ENDOCRINOLOGY (2017)
Glucagon-like peptide- I receptor agonists: a systematic review of comparative effectiveness research
Philip A. Levin et al.
DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY (2017)
Insulin glargine 300 U/mL for basal insulin therapy in type 1 and type 2 diabetes mellitus
Ip Tim Lau et al.
DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY (2017)
Three-year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: Long-term efficacy with or without rescue therapy
Philip D. Home et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2017)
Microvascular effects of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled trials
Ilaria Dicembrini et al.
ACTA DIABETOLOGICA (2017)
Sodium-glucose cotransporter 2 (SGLT2) inhibitors and fracture risk in patients with type 2 diabetes mellitus: A meta-analysis
Darin Ruanpeng et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2017)
Incretin-based glucose-lowering medications and the risk of acute pancreatitis and/or pancreatic cancer: Reassuring data from cardio-vascular outcome trials
Michael A. Nauck et al.
DIABETES OBESITY & METABOLISM (2017)
Cancer risk among insulin users: comparing analogues with human insulin in the CARING five-country cohort study
Anna But et al.
DIABETOLOGIA (2017)
Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): Data from randomized controlled trials
Matteo Monami et al.
DIABETES OBESITY & METABOLISM (2017)
Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes
Simon J. Griffin et al.
DIABETOLOGIA (2017)
Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors
Michael A. Nauck et al.
CIRCULATION (2017)
Effects of SGLT-2 inhibitors on diabetic ketoacidosis: A meta-analysis of randomised controlled trials
Matteo Monami et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2017)
SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System
Gian Paolo Fadini et al.
DIABETOLOGIA (2017)
Faster Aspart Versus Insulin Aspart as Part of a Basal-Bolus Regimen in Inadequately Controlled Type 2 Diabetes: The onset 2 Trial
Keith Bowering et al.
DIABETES CARE (2017)
Efficacy of the Telemedical Lifestyle intervention Program TeLiPro in Advanced Stages of Type 2 Diabetes: A Randomized Controlled Trial
Kerstin Kempf et al.
DIABETES CARE (2017)
Albiglutide for the treatment of type 2 diabetes mellitus: An integrated safety analysis of the HARMONY phase 3 trials
Bo Ahren et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2017)
Sulfonylureas and the Risks of Cardiovascular Events and Death: A Methodological Meta-Regression Analysis of the Observational Studies
Laurent Azoulay et al.
DIABETES CARE (2017)
Insulin and Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials
Maria Ida Maiorino et al.
DIABETES CARE (2017)
Elevated serum uric acid and risk of cardiovascular or all-cause mortality in people with suspected or definite coronary artery disease: A meta-analysis
Ruijuan Wang et al.
ATHEROSCLEROSIS (2016)
CV Protection in the EMPA-REG OUTCOME Trial: A Thrifty Substrate Hypothesis
Ele Ferrannini et al.
DIABETES CARE (2016)
Lack of evidence for a harmful effect of sodium-glucose co-transporter 2 (SGLT2) inhibitors on fracture risk among type 2 diabetes patients: a network and cumulative meta-analysis of randomized controlled trials
H. L. Tang et al.
DIABETES OBESITY & METABOLISM (2016)
SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?
Naveed Sattar et al.
DIABETOLOGIA (2016)
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Alberico L. Catapano et al.
EUROPEAN HEART JOURNAL (2016)
Comparison of Clinical Outcomes and Adverse Events Associated With Glucose-Lowering Drugs in Patients With Type 2 Diabetes A Meta-analysis
Suetonia C. Palmer et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Christoph Wanner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies
Ling Li et al.
BMJ-BRITISH MEDICAL JOURNAL (2016)
Correction: The Association between Sulfonylurea Use and All-Cause and Cardiovascular Mortality: A Meta-Analysis with Trial Sequential Analysis of Randomized Clinical Trials
Dimitris Varvaki Rados et al.
PLOS MEDICINE (2016)
Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies
Ling Li et al.
BMJ-BRITISH MEDICAL JOURNAL (2016)
Association Between Incretin-Based Drugs and the Risk of Acute Pancreatitis
Laurent Azoulay et al.
JAMA INTERNAL MEDICINE (2016)
Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomised clinical trial
Edward W. Gregg et al.
LANCET DIABETES & ENDOCRINOLOGY (2016)
Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis
Heidi Storgaard et al.
PLOS ONE (2016)
Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA®)
Nikolaus Marx et al.
DIABETES & VASCULAR DISEASE RESEARCH (2015)
Comparison of the Pharmacokinetics and Pharmacodynamics of LY2963016 Insulin Glargine and EU- and US-Approved Versions of Lantus Insulin Glargine in Healthy Subjects: Three Randomized Euglycemic Clamp Studies
Helle Linnebjerg et al.
DIABETES CARE (2015)
Similar efficacy and safety of LY2963016 insulin glargine and insulin glargine (Lantus (R)) in patients with type 2 diabetes who were insulin-naive or previously treated with insulin glargine: a randomized, double-blind controlled trial (the ELEMENT 2 study)
J. Rosenstock et al.
DIABETES OBESITY & METABOLISM (2015)
Faster-acting insulin aspart: earlier onset of appearance and greater early pharmacokinetic and pharmacodynamic effects than insulin aspart
T. Heise et al.
DIABETES OBESITY & METABOLISM (2015)
Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo-controlled trial
A. Ahmann et al.
DIABETES OBESITY & METABOLISM (2015)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
A Randomized Trial of Intensive versus Standard Blood-Pressure Control
Jackson T. Wright et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Jennifer B. Green et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Relation of active, passive, and quitting smoking with incident type 2 diabetes: a systematic review and meta-analysis
An Pan et al.
LANCET DIABETES & ENDOCRINOLOGY (2015)
Mortality risk among sulfonylureas: a systematic review and network meta-analysis
Scot H. Simpson et al.
LANCET DIABETES & ENDOCRINOLOGY (2015)
Using real-world data to evaluate the association of incretin-based therapies with risk of acute pancreatitis: a meta-analysis of 1 324 515 patients from observational studies
T. Wang et al.
DIABETES OBESITY & METABOLISM (2015)
Glucagon-Like Peptide 1 Receptor Agonist or Bolus Insulin With Optimized Basal Insulin in Type 2 Diabetes
Michaela Diamant et al.
DIABETES CARE (2014)
Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes
Stephen C. L. Gough et al.
LANCET DIABETES & ENDOCRINOLOGY (2014)
Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials
M. Monami et al.
DIABETES OBESITY & METABOLISM (2013)
Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
William B. White et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Cardiovascular Effects of Intensive Lifestyle Intervention in Type 2 Diabetes
Rena Wing et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
Benjamin M. Scirica et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Harmonizing the Metabolic Syndrome A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity
K. G. M. M. Alberti et al.
CIRCULATION (2009)
分享论文
